Understanding heart risks from cancer immunotherapy
Official title: Risk Assessment and Outcomes Across the Clinical Spectrum of Cardiotoxicity from Immune Checkpoint Inhibitors
Funded at Stanford University · NIH-10996621 · Data updated 2026-11-12
This study is looking at how cancer treatments called immune checkpoint inhibitors might affect the heart, especially in patients with certain heart markers, to help figure out who can safely keep using these treatments even if they have heart symptoms.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $83,932 |
| NIH project number | 1F32HL176198-01 |
| Project ID | NIH-10996621 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients receiving immune checkpoint inhibitors who may be experiencing or at risk for heart-related side effects.
✕Less likely to help
Patients who are not undergoing treatment with immune checkpoint inhibitors or those without any cardiovascular concerns may not benefit from this research.
What this research studies
This research investigates the heart-related side effects of immune checkpoint inhibitors (ICIs), which are treatments for cancer. It aims to identify how different patients experience cardiotoxicity, particularly focusing on those with abnormal troponin-I levels. By analyzing both past and current patient data, the study seeks to determine which patients can safely continue their cancer treatment despite experiencing heart-related symptoms. The goal is to improve patient safety and treatment outcomes by better understanding the risks associated with these therapies.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatment options for patients experiencing heart-related side effects from immunotherapy.
How similar studies have gone: Previous research has shown promising results in monitoring and managing cardiotoxicity in cancer patients, indicating that this approach has potential for success.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Cheng, Evaline — Stanford University
- Study coordinator: Cheng, Evaline
Related research
Other NIH-funded projects on the same topics.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.